Oncology Conference London 2027

Why this room

Oncology conference London: a senior room, not a busy aisle

If you sell trial, regulatory or commercial services to cancer drug developers, ImmunoMark Summit is the oncology conference London service providers can use to sit down with the people who choose CROs, consultancies and agencies.

Generalist pharma events mix every therapy area, so a services BD team spends most of the day qualifying people out. At ImmunoMark every delegate works on immuno-oncology or on the biomarkers and companion diagnostics that sit behind it. That narrows the room to the programmes you can actually support, and it changes the maths of the two days: fewer conversations wasted, more of them with a live oncology asset behind them.

The 2nd annual London edition runs on 3–4 March 2027 and targets 400+ delegates, with 60% from the UK and Ireland and 40% from the rest of Europe. Organised by Convolign Business Consulting, it runs two parallel streams: Next-Gen Immuno-Oncology (NGIO) and Biomarkers & Companion Diagnostics.

300+delegates at London 2026

100+companies took part in 2026

70%senior decision-makers in 2026

15–25meetings per sponsor in 2026

Companies that took part in 2026 included GSK, Roche, AstraZeneca, Bristol Myers Squibb, Incyte and Pierre Fabre, alongside UK biotechs such as Leucid Bio and ValiRx. For a services firm that mix is useful: large pharma teams bring established vendor processes, while smaller biotechs are still building the partner list that will carry an asset through the clinic. Few oncology events London hosts give you both groups in a room of this size.

Who you will meet

The buyer roles behind oncology services, and what they are evaluating

The London prospectus lists clinical development, translational medicine, regulatory affairs, CDx, precision medicine and business development among the key departments. Here is how those roles map to what you sell, and the real London 2027 session most likely to bring each one into the room.

Buyer role	What they are evaluating	London 2027 session to plan around
Clinical development and clinical operations leads	CRO capacity for IO trials, adaptive and biomarker-driven designs, patient selection	Clinical Trial Design in Immunotherapy: Adaptive & Biomarker-Driven Models (Day 1, Stream 1)
Medical and safety leads	Safety monitoring and risk management for combination and cell-based regimens	Precision Safety Management & Risk Mitigation in IO (Day 1, Stream 1)
Regulatory affairs	EMA, FDA and MHRA strategy for drugs and their companion diagnostics	Panel: Global CDx Approval Pathways – EMA, FDA & MHRA Perspectives (Day 2, Stream 2)
Market access and commercial leads	Reimbursement evidence, value dossiers, launch readiness	Companion Diagnostics Commercialisation & Reimbursement Strategy (Day 2, Stream 2)
Translational and biomarker leads	Data strategy, real-world evidence and biomarker analysis support	Real-World Evidence Integration into Biomarker Strategy (Day 2, Stream 2)
BD, licensing and strategy leads	Partners for scale-up, licensing readiness and investor-facing work	Investment & Partnership Models in Immunotherapy (Day 2, Stream 1)

Seniority supports the case. The prospectus puts 45–50% of delegates in senior leadership (executives, directors and heads) and 10–15% in management, marketing and commercial roles, which is where agency and communications briefs usually start. The speaker faculty points the same way: Ivan Diaz-Padilla, Senior Vice President and Global Head of Oncology R&D at Ipsen, gives the Day 2 Stream 1 keynote on next-gen combination immunotherapies, and the panel includes Ketki Flannery, Associate Director, Cell Manufacturing and CMC at Autolus Ltd, and a clinical expert from NICE. Those are the conversations that shape outsourcing and access decisions.

How the meetings work

Turning a two-day summit into a services pipeline

A booth alone rarely wins a CRO or market-access contract. The pre-scheduled 1:1 meetings are where services sponsors get value, and this is how a BD team should run them.

Choose your streamPlatinum, Gold and Silver sponsors pick NGIO or Biomarkers & CDx. Trial-delivery CROs usually sit best in Stream 1, where trial design and safety sessions run; regulatory, CDx and access consultancies fit Stream 2.
Shortlist from full profilesTen days before the event you receive the full delegate list with profiles. Filter by role and company stage, not only by logo: a Phase 1 biotech with one IO asset can be a faster sale than a top-ten pharma.
Add a wishlistThe wishlist feature flags the people you most want to reach beyond your meeting allocation, so the team can target them during breaks.
Book 20-minute slots around the sessionsSchedule meetings next to the sessions your buyers sit in, using the table above. A regulatory lead coming out of the CDx approval panel is ready to talk about submissions.
Use the Day 1 drinks receptionThe reception at the end of Day 1 is the place for second conversations with buyers you met that morning, and for introducing your scientific lead.
Follow up from the delegate listEvery tier includes the delegate list with contact details, so follow-up does not depend on badge scans.

Treat this as a different exercise from a large oncology congress London teams might staff for brand presence. Here the unit of value is a booked meeting with a named buyer, and the plan should be built backwards from that.

Packages

Which packages fit oncology service providers

Services are bought in conversations, so weight your choice towards pre-scheduled meetings and a speaking slot that shows your team’s thinking. Every tier includes the delegate list with contact details and post-event branding.

Best fit

Platinum

For CROs and pharma-services firms that want a Day 1 platform in their chosen stream plus enough meetings to fill a sales calendar.

10 pre-scheduled 1:1 meetings
30-minute Day 1 talk in your stream
Email campaign to registered delegates
Attendee list a week before the event
8 team passes plus 8 client passes
10 x 6 ft booth and 1-minute video promotion

Gold

For specialist CROs, medical communications and access agencies with one sharp offer to present.

6 pre-scheduled 1:1 meetings
30-minute talk on Day 2, pre-lunch
10 x 6 ft booth
6 team passes plus 6 client passes
Half-page brochure advertisement

Exclusive 1:1 Meetings

For consultancies whose sale is a senior conversation, not a stand.

3, 5, 7 or 10 meetings of 20 minutes
2–4 delegate passes
Drinks reception passes
Wishlist and delegate list

One company can take the exclusive Headline package: 15 meetings, the Day 1 welcome speech plus a 30-minute keynote slot across both streams, a 20 x 12 ft space, an email campaign to the full pre-qualified database and “Powered by” branding. The client passes in Platinum and Gold are worth planning early: inviting an existing biotech client lets you show the relationship in front of prospects. Full details are on the London sponsorship page.

Model what 6, 10 or 15 meetings are worth against your average contract value.

Estimate your return

Planning

Where the oncology conference London 2027 slot fits in your plan

Early March sits at the start of most budget years, before the busier spring and summer congress season. For a services team that means meetings land while buyers are still placing work for the year.

London as your European base

With 40% of delegates from continental Europe, one London presence reaches UK biotechs and European pharma teams in the same two days.

Selling in the US as well

The San Diego launch edition runs on 10–11 February 2027. See the San Diego page for service providers to pair the two.

CDx or regulatory services

If your offer is co-development or IVDR and MHRA support, the companion diagnostics view of London goes deeper on Stream 2.

Among the oncology conferences London has to offer, ImmunoMark is the focused, meeting-led option rather than the volume play; if you are still mapping the wider calendar, our guide to pharma conferences in London sets out what each type of event delivers. For a checklist on comparing events, read how to choose biotech conferences to sponsor. Think of it as an oncology summit London buyers come to for depth, and plan your team accordingly: one BD lead, one scientific or medical lead, and a calendar built around meetings.

Get the London prospectus and current package availability.

Request the prospectus

What sponsors said

Feedback from London 2026 sponsors

Here is what sponsors told us at our London 2026 launch edition.

We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.

Project Manager

PromoCell GmbH · Sponsor, London 2026

We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.

BD Manager Europe

Secretech · Sponsor, London 2026

Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.

Research Account Manager

Miltenyi Biotec · Sponsor, London 2026

My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.

Senior Business Development Director Europe

Rouken Bio · Sponsor, London 2026

We got the occasion to discuss customer projects and understand their needs better and how we can help them.

Epigenomics Applications Specialist

Hologic Diagenode · Sponsor, London 2026

The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.

Biopharma Business Development Manager EMEA

Hologic Diagenode · Sponsor, London 2026

Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.

Business Development Executive

HistologiX · Sponsor, London 2026

The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.

Product Specialist

HAWK Biosystems · Sponsor, London 2026

Get the prospectus

Frequently asked questions

Who will a CRO or services firm meet at the London oncology conference?

The prospectus puts 55–60% of delegates in biotech and pharma and 45–50% in senior leadership roles. Key departments include clinical development and operations, translational medicine, regulatory affairs, companion diagnostics, precision medicine and business development. At London 2026, 70% of the 300+ delegates were senior decision-makers.

Can we choose which delegates our team meets?

Yes. Ten days before the event you receive the full delegate list with profiles and choose who you want to meet. Meetings last 20 minutes. Headline includes 15, Platinum 10 and Gold 6, and the Exclusive 1:1 Meetings packages offer 3, 5, 7 or 10. Silver and Exhibitor packages have no pre-scheduled meetings but include the wishlist and the delegate list.

Which stream should a CRO or medical communications agency choose?

Platinum, Gold and Silver sponsors choose one stream. Trial-delivery CROs usually fit Stream 1 (Next-Gen Immuno-Oncology), where sessions on trial design and safety management run. Regulatory, CDx and market-access specialists usually fit Stream 2 (Biomarkers & Companion Diagnostics). Your 1:1 meetings can be with delegates from either stream.

What meeting volumes did services sponsors see at London 2026?

The post-show report records 200+ meetings conducted, 15–25 meetings per sponsor and 55+ pre-scheduled 1:1 meetings for title sponsors. The 2026 edition had 300+ delegates from 100+ companies, including GSK, Roche, AstraZeneca and Bristol Myers Squibb. The 2027 target is 400+ delegates.

Can we bring existing clients to the summit?

Yes. Most packages include client passes alongside your team passes: 10 with Headline, 8 with Platinum, 6 with Gold, 4 with Silver and 2 with Exhibitor. Many services sponsors use them to host a current biotech client, which gives prospects a reference in the room.

Oncology Conference London for CROs and Service Providers

Get the prospectus and package availability